Komori
Earnings presentation4971MEC COMPANY LTD.Materials and Chemicals

Materials for the Financial Results Briefing for the Fiscal Year Ended December 2023

2023年12月期は、薬品の出荷量減少などにより減収減益となり、売上高は前期比14.1％減、営業利益は同37.7％減となった。2024年12月期は売上高・営業利益の回復を見込む一方、純利益は減少する予想。

Worth reading
67In focus
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
2309
¥ million (year-on-year decrease in revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Earnings presentationFiscal year ended December 202312 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥14,020 million-14.1%
Operating profit¥2,492 million-37.7%
Ordinary income¥2,683 million-36.8%
Net income¥2,304 million-24.8%
Selling, general and administrative expenses¥5,824 million
Gross Profit Margin
Rate59.3%
Year on year against the same period last year△0.7ppt
Operating profit margin
Rate17.8%
Year on year against the same period last year△6.7ppt
Full-year earnings forecast
Net Sales
¥16,300 million
Operating profit
¥3,000 million
Ordinary income
¥3,100 million
Net income
¥2,150 million
Earnings per share
¥114.82
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • 為替の影響（売上高）¥305 million
    DirectionIncreased
  • 為替の影響（営業利益）¥111 million
    DirectionIncreased
  • 密着向上剤・エッチング剤・その他薬品・機械・資材・その他売上等
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • ¥4.37
    AssumptionsNTD期中平均レート
  • ¥19.33
    AssumptionsRMB期中平均レート
  • ¥128.03
    AssumptionsUSD期中平均レート
  • 30,000 t/年予定
    Assumptions北九州工場の生産能力
New initiatives
  • 北九州工場（仮称）の建設
    Total investment4,000
    Construction start2024年4月予定
    Operations2025年7月予定
    Production Capacity約30,000t/年（予定）
  • 化学密着向上剤APシリーズの開発
    SituationUnder Development
  • 新規事業の創出・既存技術の応用展開
    DetailsExpansion into New Business Areas
Key KPIsA metric the company considers important as a management benchmark.
  • 薬品出荷量35,398 t-21.3%
  • Overseas revenue ratio61.1 %
  • ROE9.6 %
  • EBITDA¥3,993 million-20.0%
Segment results
  • Chemicals
    Net Sales¥13,764 million
    Year on year against the same period last year-14.2%
  • Machinery
  • Materials
  • Other
  • 地域別・日本
  • 地域別・台湾
  • 地域別・中国
  • 地域別・欧州
  • 地域別・タイ
Medium-term management plan targets
Consolidated payout ratio30%
ROE10%以上（2024年目標）
Financial targets
ROE
Target10%以上（2024年）
Actual results9.6%
Number of employees
Consolidated454 people
Standalone263 people
Capital expenditures
¥1,377 millionFY2023
Annual Dividend
2024年12月期予想
Annual¥45
Interim¥20
End of period¥25
2023年12月期実績
Annual¥45
Interim¥20
End of period¥25
Payout ratio
2024年12月期予想39.2 %
2023年12月期実績36.8 %
Medium-term target30 %
Acquisition of treasury shares
899.86
Number of Shares286,000
Amount unit¥ million
Period2023年5月11日〜2023年6月23日
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredFiscal year ended December 2023
Net Sales¥14,020 million (YoY -14.1%)
Operating profit¥2,492 million (YoY -37.7%)
Ordinary income¥2,683 million (YoY -36.8%)
Net income¥2,304 million (YoY -24.8%)
Gross Profit MarginRate 59.3% / Year on year against the same period last year △0.7ppt
Operating profit marginRate 17.8% / Year on year against the same period last year △6.7ppt
Selling, general and administrative expenses¥5,824 million
Full-year earnings forecastNet Sales ¥16,300 million / Operating profit ¥3,000 million / Ordinary income ¥3,100 million / Net income ¥2,150 million / Earnings per share ¥114.82
Segment resultsCategory Chemicals / Net Sales ¥13,764 million / Year on year against the same period last year -14.2, Category Machinery / Net Sales Not disclosed, Category Materials / Net Sales Not disclosed, Category Other / Net Sales Not disclosed, Category 地域別・日本 / Net Sales Not disclosed, Category 地域別・台湾 / Net Sales Not disclosed, Category 地域別・中国 / Net Sales Not disclosed, Category 地域別・欧州 / Net Sales Not disclosed, Category 地域別・タイ / Net Sales Not disclosed
Breakdown of Factors Affecting the ChangeFactors 為替の影響（売上高） / Amount ¥305 million / Direction Increased, Factors 為替の影響（営業利益） / Amount ¥111 million / Direction Increased, Factors 密着向上剤・エッチング剤・その他薬品・機械・資材・その他売上等 / Amount Not disclosed
Key KPIs35,398 t (YoY -21.3%), 61.1 %, 9.6 %, ¥3,993 million (YoY -20.0%)
Number of employeesConsolidated 454 people / Standalone 263 people
Assumptions Underlying the Business Outlook¥4.37, ¥19.33, ¥128.03, 30,000 t/年（予定）
Medium-term management plan targetsConsolidated payout ratio 30% / ROE 10%以上（2024年目標）
Financial targetsROE Target 10%以上（2024年） / Actual results 9.6%
Annual Dividend2024年12月期予想 Annual ¥45 / Interim ¥20 / End of period ¥25 / 2023年12月期実績 Annual ¥45 / Interim ¥20 / End of period ¥25
Payout ratio2024年12月期予想 39.2 % / 2023年12月期実績 36.8 % / Medium-term target 30 %
Acquisition of treasury sharesNumber of Shares 286,000 / Amount 899.86 / Amount unit ¥ million / Period 2023年5月11日〜2023年6月23日
Capital expenditures1,377 百万円（FY2023）
New initiativesMeasures 北九州工場（仮称）の建設 / Total investment ¥4,000 million / Construction start 2024年4月予定 / Operations 2025年7月予定 / Production Capacity 約30,000t/年（予定）, Measures 化学密着向上剤APシリーズの開発 / Situation Under Development, Measures 新規事業の創出・既存技術の応用展開 / Details Expansion into New Business Areas
Items this document does not state (9)
Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

会社は、短期的な半導体市況の調整や個人消費の停滞の影響を見込んでいる。2023年12月期については、薬品出荷量が前期比21.3％減少し、主要製品ではSFなどの売上が減少した。一方、為替は売上高305百万円、営業利益111百万円の増加要因となった。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Materials for the Financial Results Briefing for the Fiscal Year Ended December 2023 | MEC COMPANY LTD. (4971) timely disclosure | Komori